Metformin- a simple, once-daily medication originally used to treat diabetes—may also help support glucose control, encourage weight loss, and reduce the risk of certain age-related diseases. Prescription needed but can be done online and longevity can be a reason.
May be an affiliate link, see footer.
Metformin has robust observational data (including large cohort studies suggesting diabetic patients on metformin outlive non-diabetic controls) and strong mechanistic plausibility for anti-aging effects, but no completed RCT (randomized controlled trial) has yet confirmed longevity or healthspan benefits in non-diabetic humans. The landmark TAME (Targeting Aging with Metformin) trial is ongoing and will be the key test.
Metformin is a biguanide drug that primarily activates AMPK (AMP-activated protein kinase), reducing hepatic glucose production and improving insulin sensitivity. In the context of longevity, it is hypothesized to mimic caloric restriction signaling, reduce mTOR (mechanistic target of rapamycin) activity, lower systemic inflammation, and attenuate cellular senescence — pathways mechanistically linked to aging.
Observational
“Aging represents a complex biological phenomenon marked by the progressive deterioration of physiological functions over time, reduced resilience, and increased vulnerability to age-related diseases, ultimately culminating in mortality.”
“Aging is a multifactorial biological process involving chronic diseases that manifest from the molecular level to the systemic level.”
“The increase in life expectancy has boosted the incidence of age-related pathologies beyond social and economic sustainability.”
“Metformin and exercise independently improve insulin sensitivity and decrease the risk of diabetes.”
All longevity evidence in humans is observational and confounded (e.g., healthy-user bias in diabetic cohorts). Metformin may blunt exercise adaptations — several RCTs show it attenuates mitochondrial biogenesis and muscle protein synthesis gains from resistance training, a real concern for active users. It is a prescription drug being marketed in a supplement context, raising regulatory and safety framing issues. Gastrointestinal side effects are common. B12 deficiency is a known long-term risk. The TAME trial is not yet complete, so efficacy in healthy aging adults remains unproven.
EOD publishes opinions and summaries of research about supplements, services, and protocols. It is not medical advice. Consult a qualified healthcare provider before changing your supplement, exercise, sleep, or medication regimen.
Some outbound links on EOD are affiliate links. If you buy through them we may earn a small commission, at no extra cost to you. It never influences what we publish or how it's ranked. Full disclosure.
EOD · 123 Placeholder Street, New York, NY 10001